一种新的每日药片, 恩利西提德 (enlicitide) 在一项大型试验中降低了60%的LDL胆固醇, 为高危患者提供了一个有前途的口服替代品. A new daily pill, enlicitide, lowered LDL cholesterol by 60% in a major trial, offering a promising oral alternative for high-risk patients.

一种新药,每天服用一次的恩利西提德 (enlicitide), 在一个大规模的第三期试验中降低了60%左右的LDL胆固醇. 这是自他类药物以来用口服药物的最大下降. A new once-daily pill, enlicitide, reduced LDL cholesterol by about 60% in a large phase three trial, the largest drop seen with an oral medication since statins. 这种仿效注射治疗的药物可以帮助那些高剂量他类药物的患者达到胆固醇目标. The drug, which mimics injectable treatments, may help patients who don’t reach cholesterol targets with high-dose statins. 研究人员说, 这种药物可以显著降低心脏病发作和中风的危险, 对于高患心血管疾病的人来说是一个有前途的选择. Researchers say it could significantly lower heart attack and stroke risk, offering a promising option for those at high cardiovascular risk.